PROVIDER BULLETIN

TOPIC: Marinol (Dronabinal)

Published by Wyoming Workers’ Compensation Medical Case Management Unit  
February, 2016

Based on the research, the use of Marinol for non-malignant pain will be denied by the Division. Any requests for use by a provider will considered investigational and according to the Wyoming Workers’ Compensation Rules & Regulations, Chapter 10, Section 19., (the provider) …will submit to the Division a comprehensive review of the medical literature. This review will include at least two good prospective, randomized, placebo-controlled, double-blind trials.

Per the FDA, Marinol is only approved for the treatment of nausea.

The request for Marinol, in addition to the studies provided will be sent to a pain management specialist for review.

Final decision as to the approval or denial of the request will be made at the administrative level by the District Manager and/or Deputy Administrator.